Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

Bilici, Ahmet; Uysal, Mukremin; Menekse, Serkan; Akin, Semih; Yildiz, Fatih; Turan, Merve; SEZGİN GÖKSU, SEMA; Beypinar, Ismail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Basaran, Gul; Olmez, Omer; Avci, Nilufer; Tural, Deniz; Sakin, Abdullah; Turker, Sema; Demir, Atakan; Temiz, Suleyman; Kaplan, Muhammed; Dogan, Mutlu; Tanriverdi, Ozgur; Bilgetekin, Irem; Cinkir, Havva; Acikgoz, Ozgur; Paydas, Semra; Uslu, Ruchan; Turhal, Serdar

doi:10.1080/07357907.2021.2017952

Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

Copy For Citation

Bilici A., Uysal M., Menekse S., Akin S., Yildiz F., Turan M., ...More

Cancer Investigation, vol.40, no.2, pp.199-209, 2022 (SCI-Expanded)

Publication Type: Article / Article
Volume: 40 Issue: 2
Publication Date: 2022
Doi Number: 10.1080/07357907.2021.2017952
Journal Name: Cancer Investigation
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.199-209
Keywords: Everolimus, exemestane, metastatic breast cancer, hormone receptor-positive, HER - negative, efficacy, AROMATASE INHIBITORS, SURVIVAL, MTOR, HR+, CHEMOTHERAPY, SENSITIVITY, COMBINATION, GUIDELINES, RESISTANCE, THERAPIES
Kayseri University Affiliated: No

Abstract

© 2021 Taylor & Francis Group, LLC.Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) patients in real-life settings. Methods: Overall, 204 HR+, HER2− MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results: The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion: We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER − MBC patients.